January 6, 2017

Study shows promising results for treating lymphoma patients with immune cell therapy
News Medical – Jan. 6
Moffitt Cancer Center physician investigators are working to bring immune cellular therapies to refractory diffuse large B-cell lymphoma patients.

Adding epoetin alfa to lenalidomide boosted myelodysplastic syndrome responses
Hematology News – Jan. 5
After 16 weeks of treatment, 33% of patients who received both lenalidomide and epoetin alfa met International Working Group 2000 criteria for major erythroid response, compared with only 14% of patients receiving lenalidomide monotherapy (P = .03), Alan F. List, MD, reported at the annual meeting of the American Society of Hematology.

Understanding the recent WHO MDS Classification updates
OncLive – Jan. 5
I am Dr. Vinod Pullarkat, and I am associate clinical professor of hematology and hematopoietic cell transplantation at the City of Hope Medical Center in Duarte, California. Participating today on our distinguished panel are: Dr. Rami Komrokji, clinical director, senior member, and professor of oncologic sciences for the Malignant Hematology Department at the Moffitt Cancer Center in Tampa, Florida; Dr. Thomas Prebet, assistant director of Myeloid Malignancy Research and associate professor of hematology at the Yale Cancer Center in New Haven, Connecticut; Dr. Ellen K. Ritchie, an assistant professor of clinical medicine at Weill Cornell Medical College affiliated with New York Presbyterian Hospital; and Dr. Jamile Shammo, associate professor of medicine and pathology at the Rush University Medical Center in Chicago, Illinois. Thank you all for joining us.

It’s tough to telecommute in health care
Advisory – Jan. 5
Yvonne Chase, manager of patient access and billing services for Mayo Clinic's Florida and Arizona campuses, and Lynne Hildreth, director of revenue cycle and patient access at Moffitt Cancer Center in Tampa, says letting employees work remotely at their organizations has been worthwhile.

Immune cell therapy shows promising results for lymphoma patients
Science Daily – Jan. 5
Moffitt Cancer Center physician investigators are working to bring immune cellular therapies to refractory diffuse large B-cell lymphoma patients.

Editorial: Tampa Bay's leadership on immunotherapy
Tampa Bay Times – Jan. 5
Moffitt Cancer Center in Tampa is on the cusp of obtaining approval for experimental treatments that have already helped patients there. 

Anti-HER2 Dendritic Vaccine Showing Promise in Early Breast Cancer Patients
OncoTherapy Network – Jan. 5
“These results suggest that vaccines are more effective in DCIS, thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint,” said Brian Czerniecki, MD, PhD, Chair of the Department of Breast Oncology at Moffitt Cancer Center, Tampa, Fla.

Why Most Women Shouldn’t Undergo BRCA Testing for Breast Cancer Risk
US News and World Report – Jan. 5
“The recommendation would be high-risk screening following the breast cancer diagnosis through breast MRIs and mammograms yearly,” says Dr. Tuya Pal, a clinical geneticist at Moffitt Cancer Center in Tampa, Florida.

OncoBreak: Fewer Cancer Deaths; Hot Anticancer Protein; War and Cancer
MedPage Today – Jan. 5
A breast cancer vaccine directed against HER2 protein showed preliminary signs of activity. (Moffitt Cancer Center)

New Breast Cancer Vaccine Shows Promise In Curbing Deadly Disease
Counsel & Heal – Jan. 5
Now, researchers at the Moffitt Cancer Center is working on a new vaccine that targets the HER2 protein on breast cancer cells, which results in a slowdown in the progression of cancer.

Trial Offers New Hope for Breast Cancer Vaccine
NewsMax  – Jan. 5
The Holy Grail in the fight against breast cancer is to develop a vaccine that would target cancer cells for destruction. And researchers at Moffitt Cancer Center may have that goal within their reach.

Shannen Doherty Swears By Exercise To Feel Better, Cancer Be Damned
Self Magazine – Jan. 5
Exercise doesn’t just improve symptoms—in the right situation, it can also increase a person’s survival, she says. Ron Jennings, a physical therapist at Moffitt Cancer Center, agrees. “To fight cancer, you have to keep moving and stay strong,” he tells SELF.

Immune Cell Therapy Shows Promising Results For Lymphoma Patients, Says Moffitt Researchers
PublicNow – Jan. 5
Moffitt Cancer Center physician investigators are working to bring immune cellular therapies to refractory diffuse large B-cell lymphoma patients. Promising results from the phase 1 portion of the ZUMA-1 study, which uses chimeric antigen receptor (CAR) modified T cells to treat b-cell lymphoma patients, were published in the January issue of Molecular Therapy, the official journal of the American Society of Gene and Cell Therapy.

Vaccino contro il tumore al seno: ai test risultato sicuro e efficace
Il Giornale – Jan. 5
I ricercatori del Moffitt Cancer Center, infatti, hanno realizzato e testato un vaccino in grado di aiutare il sitema immunitario di un malato di cancro a sviluppare anticorpi in grado di aggredire la proteina HER2 presente nelle cellule tumorali. 

Avances en una vacuna contra cáncer de mama
Ansa Latina – Jan. 5
El gen HER2 abunda en el 25 por ciento de todos los cánceres de mama y está asociado con una enfermedad agresiva y un mal pronóstico. Los investigadores del Moffitt Cancer Center desarrollaron así una vacuna que ayuda al sistema inmunitario a reconocerlo y ponerlo en la mira.

Clinical activity, minimal toxicities for HER2-targeted dendritic cell vaccines in early breast cancer patients
eCancer News – Jan. 5
Researchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.

Researchers use mathematical modeling to explain evolutionary phenomenon that leads to treatment resistance
eCancer News – Jan. 5
A collaborative team of researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Program, led by Alexander Anderson, Ph.D., and Oxford University’s Department of Computer Science are using mathematical models to explain how bacteria and cancer cells exploit an evolutionary process known as bet-hedging to resist medical intervention.

M2Gen Announces That Merck & Co. Joins The Oncology Research Information Exchange Network (ORIEN) Avatar Research Program
BioSpace.com – Jan. 5
"We are thrilled to once again be working with Merck, who we view as a founding partner in Total Cancer Care," said William Dalton, PhD, MD, founder and CEO of M2Gen. "We look forward to the next chapter in our shared mission to transform the way in which we diagnose, study and treat cancer patients."

Promising new vaccine could use your own cells to fight breast cancer
She Knows – Jan. 4
Researchers from the Moffitt Cancer Center in Tampa, Florida, are testing a new vaccine that could potentially activate the body’s immune system cells to target the HER2 protein on breast cancer cells in early-stage breast cancer patients.

Breast cancer vaccine displays promising results
Becker’s Hospital Review – Jan. 4
"These results suggest that vaccines are more effective in disease called ductal carcinoma in situ [cancer that begins in the milk ducts], hereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint," said study author Brian J. Czerniecki, MD, PhD, chair of the Department of Breast Oncology at Moffitt Cancer Center in Tampa, Fla.

Breast Cancer Vaccine Shows Promising Results In Early-Stage Patients
iTech Post – Jan. 4
The breast cancer vaccine is being developed solely to attack specific proteins that carry the HER2. According to the Science Daily, researchers from Moffitt Cancer Care Center used dendritic cells, obtained from the patient's blood, to target the protein. 

GARD Brings Personalized Medicine to Radiotherapy\
Medscape – Jan. 4
"Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours," write lead author Jacob Scott, MD, Moffitt Cancer Center and Research Institute, Tampa, Florida, and colleagues.

Tumore al seno il vaccine risulta “sicuro ed efficace
Zazoom Social News – Jan. 4
È risultato “sicuro ed efficace” il vaccino terapeutico contro il Tumore al seno. I ricercatori del Moffitt Cancer Center hanno sviluppato un vaccino in grado di aiutare il sistema immunitario a prendere di mira la proteina HER2 sulle cellule del cancro alla mammella.

Novel Dendritic Cell Vaccine Shows Promising Result for Early-Stage Breast Cancer
MedIndia.net – Jan. 4
A new dendritic cell vaccine that targets the HER2 (human epidermal growth factor receptor 2) protein present in the breast cancer cells may be safe and effective in stimulating the immune system leading to the regression of early-stage breast cancer, finds a research study from the Moffitt Cancer Center Report.

Vaccine shows promise in fight against breast cancer
The Times of India – Jan. 4
In order to determine if the HER2-dendritic cell vaccine is safe and effective, the researchers Moffitt Cancer Centre in Florida, US performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.

Promising Breast Cancer Vaccine
All4Women – Jan. 4
Could the future of breast cancer medical treatment include a vaccine? Possibly. According to Moffitt Cancer Center researchers, a dendritic cell vaccine targeting the HER2 protein on breast cancer cells is safe.

Vaccine shows promising results for early stage breast cancer patients
Medical Dialogues – Jan. 4
Researchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.

Illumina : Releases Multianalyte Tumor Profiling System
4-Traders – Jan. 3
“Having broader gene content allows us to improve cancer research by assessing more genes, and to identify structural alterations that are important targets for developing therapies,” says Anthony Magliocco, MD, chair of anatomical pathology at Moffitt Cancer Center, Tampa.

HER2-targeted dentritic cell vaccine shows promise for treating early-stage breast cancer patients
News Medical – Jan. 3
Researchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.

Vaccine shows promising results for early stage breast cancer patients
Specialty Medical Dialogues – Jan. 4
Researchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.\

Vaccine Shows Promising Results for Early-Stage Breast Cancer Patients
Tampa Patch – Jan. 3
Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease.

The Villages branch of the FCS Foundation is the only in the state with a music program
The Villages Daily Sun – Jan. 1
Tisovec, who directs the music volunteers, began the Comfort Music Players in 2012 when the Moffitt Cancer Center operated in the Sharon L. Morse Medical Building, located next to The Villages Regional Hospital. Florida Cancer Specialists and Research Institute later took over the facility and recently completed a large renovation.

Amendment 2 on Med Pot: Now Comes the Hard Part
Sunshine State News – Dec. 31
Three years ago, when this issue first came to be, Smart Justice called for an annual appropriation of $3 million a year for medical research for at least 5 years, and I’m so happy to see that future Senate President Bill Galvano is calling for research dollars for Moffitt Cancer Center and Shands Hospital. If Florida is truly going to be a leader on medical pot, and if we’re going to do it right as all elected officials desire, then Florida should take the lead to initiate proper research so that we’ll eventually be able to answer the questions as to dosage and optimal delivery methods and treatment timing for each disease based on the age and weight of the patient, and at what stage they’re in their disease.

Amy Scherzer's Diary: Weekly Wrap-Up of the Tampa Social Scene
Tampa Bay Times - Dec. 30
Memories from some of those worthy events jump out as we say "Cheers!" to a peaceful, charitable and happy new year. Faster than you can say Manolos, Bay Area Advisors sold 1,000 tickets to Martinis for Moffitt, a mostly millennial crowd thirsty for summer diversion. 

Florida senator wants state to pay for marijuana research
WJXT – Dec. 30
Galvano would send money to Moffitt Cancer Center at USF. Other universities, such as Florida A&M, may get some cash. Earlier this year, the last line of the legislation expanding the drug for use by terminally ill patients specifically allowed research in Florida universities.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.